Lipoprotein Apheresis for Lp(a)-Associated Cardiovascular Disease: 5-Year Prospective Follow-Up (Pro(a)LiFe)

The Pro(a)LiFe study prospectively followed 170 patients with Lp(a) hyperlipoproteinemia and progressive cardiovascular disease who were receiving regular lipoprotein apheresis (LA) — a procedure that mechanically removes Lp(a) and LDL from plasma — for 5 years, comparing cardiovascular event rates before and during apheresis.

Mean baseline Lp(a) was 108.1 mg/dL; LA reduced Lp(a) by 68.1% per session. LDL-C was already at guideline target before LA began (corrected LDL-C 66.3 mg/dL), confirming that the residual risk was primarily Lp(a)-driven. During the 5-year LA treatment period, the mean annual MACE rate fell from 0.58 (pre-apheresis) to 0.11 — an 81% reduction (p < 0.0001) sustained across the full follow-up.

The genetic characterization is equally important: 95.3% of patients expressed at least one small apo(a) isoform — a genetic variant associated with high Lp(a) concentrations — compared with 23.6% in the general population. Critically, SNP-based genetic testing failed to identify over one-third of high-risk patients with small isoforms, underscoring that plasma Lp(a) measurement rather than genetic testing alone is the appropriate screening strategy.

This is the largest and longest prospective study of lipoprotein apheresis for Lp(a) disease, and provides the strongest evidence that Lp(a) lowering translates to cardiovascular event reduction — a causal link that smaller Mendelian randomization studies support conceptually but that apheresis confirms functionally.

We rate the evidence moderate-strong. A well-conducted 5-year prospective study demonstrating dramatic MACE reduction with Lp(a)-targeted apheresis — the most direct clinical evidence for therapeutic Lp(a) lowering in established CVD.